Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewL-CCG-l is a potent group II metabotropic glutamate receptor agonist. More active than glutamate or (±)-trans-ACPD (Cat. No. 0187).
分子量 | 159.14 |
公式 | C6H9NO4 |
储存 | Store at RT |
纯度 | ≥99% (HPLC) |
CAS Number | 117857-93-9 |
PubChem ID | 5310956 |
InChI Key | GZOVEPYOCJWRFC-HZLVTQRSSA-N |
Smiles | N[C@]([H])(C(O)=O)[C@@]([H])(C1)[C@]1([C@@](O)=O)[H] |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
---|---|---|---|
溶解性 | |||
1eq. NaOH | 100 |
以下数据基于产品分子量 159.14。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 6.28 mL | 31.42 mL | 62.84 mL |
5 mM | 1.26 mL | 6.28 mL | 12.57 mL |
10 mM | 0.63 mL | 3.14 mL | 6.28 mL |
50 mM | 0.13 mL | 0.63 mL | 1.26 mL |
参考文献是支持产品生物活性的出版物。
Brabet et al (1998) Comparative effect of L-CCG-I, DCG-IV and γ-carboxy-L-glutamate on all cloned metabotropic glutamate receptor subtypes. Neuropharmacology 37 1043 PMID: 9833633
Hayashi et al (1992) Agonist analysis of 2-(carboxycyclopropyl)glycine isomers for cloned metabotropic glutamate receptor subtypes expressed in Chinese hamster ovary cells. Br.J.Pharmacol. 107 539 PMID: 1330184
Shinozaki et al (1989) Potent NMDA-like actions and potentiation of glutamate responses by conformational variants of a glutamate analogue in the rat spinal cord. Br.J.Pharmacol. 98 1213 PMID: 2692753
Wright and Schoepp (1996) Differentiation of group 2 and group 3 metabotropic glutamate receptor cAMP responses in the rat hippocampus. Eur.J.Pharmacol. 297 275 PMID: 8666060
If you know of a relevant reference for L-CCG-l, please let us know.
关键词: L-CCG-l, L-CCG-l supplier, Potent, group, II, mGlur, agonists, Group, Receptors, mGlu2, mGlu3, mGluR2, mGluR3, Glutamate, Metabotropic, (2S,3S,4S)-CCG, (Metabotropic), 0333, Tocris Bioscience
引用文献是使用了 Tocris 产品的出版物。 L-CCG-l 的部分引用包括:
Han et al (2015) Alleviation of kainic acid-induced brain barrier dysfunction by 4-o-methylhonokiol in in vitro and in vivo models. Biomed Res Int 2015 893163 PMID: 25688368
Scholler (2017) HTS-compatible FRET-based conformational sensors clarify membrane receptor activation. Nat Chem Biol 13 372 PMID: 28135236
Caiati et al (2012) Developmental regulation of CB1-mediated spike-time dependent depression at immature mossy fiber-CA3 synapses. Sci Rep 2 285 PMID: 22368777
Ster et al (2011) Enhancement of CA3 hippocampal network activity by activation of group II metabotropic glutamate receptors. Neuron 108 9993 PMID: 21628565
您是否知道使用了 Tocris L-CCG-l 的优秀论文? 请告知我们.
目前没有该产品的评论。 Be the first to review L-CCG-l and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.